Sitagliptin phosphate monohydrate

본문 바로가기


Home > Product > Sitagliptin phosphate monohydrate
Selling leads
Sitagliptin phosphate monohydrate
Posting date : Jun 30, 2025
Membership
Free Member Scince Jun 27, 2025
FOB Price
detailed discussion
Min. Order Quantity
1
Supply Abillity
hundreds of kgs
Port
Shanghai Port
Payment Terms
detailed discussion
Package
Convenient package
Keyword :
Category
Contact
Lena
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Royal
Model Number
+86 15242851296
HS-CODE
-
Package & Delivery Lead Time
Package
Convenient package
Detailed Description

Sitagliptinphosphate (trade name Januvia, code MK-0431), commonly known as sitagliptin, is produced by Merck in the United States. It was approved for marketing by the US Food and Drug Administration (FDA) in October 2006 for the treatment of type 2 diabetic Chemicalbook. Sitagliptin phosphate has a very ideal effect in the treatment of type 2 diabetes. As a new type of anti-diabetic drug, sitagliptin phosphate is glycemic dependent, has a moderate hypoglycemic effect, increases insulin secretion without causing hypoglycemia, effectively reduces hunger and other advantages, and has no side effects such as nausea, vomiting, edema and weight gain.


ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2025 ECROBOT.COM. All rights reserved.
Top